

John H Sampson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2444550/publications.pdf>

Version: 2024-02-01

354
papers

27,954
citations

4641

85
h-index

6818

155
g-index

359
all docs

359
docs citations

359
times ranked

20353
citing authors

#	ARTICLE	IF	CITATIONS
1	Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2007, 25, 4722-4729.	0.8	1,285
2	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 1003.	3.4	805
3	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385.	5.1	776
4	Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4722-4729.	0.8	702
5	Phase II Trial of Gefitinib in Recurrent Glioblastoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 133-142.	0.8	677
6	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , The, 2015, 16, e534-e542.	5.1	582
7	Recurrent Glioblastoma Treated with Recombinant Poliovirus. <i>New England Journal of Medicine</i> , 2018, 379, 150-161.	13.9	570
8	Challenges to curing primary brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 509-520.	12.5	540
9	Increased Regulatory T-Cell Fraction Amidst a Diminished CD4 Compartment Explains Cellular Immune Defects in Patients with Malignant Glioma. <i>Cancer Research</i> , 2006, 66, 3294-3302.	0.4	533
10	Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. <i>Journal of Neurosurgery</i> , 1998, 88, 11-20.	0.9	483
11	Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. <i>Nature Medicine</i> , 2018, 24, 1459-1468.	15.2	437
12	Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. <i>Nature</i> , 2015, 519, 366-369.	13.7	429
13	Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. <i>Neuro-Oncology</i> , 2010, 12, 871-881.	0.6	407
14	Brain immunology and immunotherapy in brain tumours. <i>Nature Reviews Cancer</i> , 2020, 20, 12-25.	12.8	389
15	Proteomic and immunologic analyses of brain tumor exosomes. <i>FASEB Journal</i> , 2009, 23, 1541-1557.	0.2	369
16	Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. <i>Neuro-Oncology</i> , 2018, 20, 674-686.	0.6	364
17	A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. <i>Neuro-Oncology</i> , 2015, 17, 854-861.	0.6	335
18	Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. <i>Neuro-Oncology</i> , 2008, 10, 10-18.	0.6	323

#	ARTICLE	IF	CITATIONS
19	Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2005, 23, 9359-9368.	0.8	313
20	Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 837-844.	0.8	313
21	Prospects of immune checkpoint modulators in the treatment of glioblastoma. <i>Nature Reviews Neurology</i> , 2015, 11, 504-514.	4.9	307
22	Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. <i>Neuro-Oncology</i> , 2011, 13, 324-333.	0.6	306
23	Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function. <i>Clinical Cancer Research</i> , 2007, 13, 2158-2167.	3.2	293
24	Phase II Trial of Temozolomide Plus O ⁶ -Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1262-1267.	0.8	280
25	An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2773-2779.	1.9	262
26	EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss. <i>Clinical Cancer Research</i> , 2014, 20, 972-984.	3.2	254
27	Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2003, 21, 646-651.	0.8	246
28	Surgical Management of Petroclival Meningiomas: Defining Resection Goals Based on Risk of Neurological Morbidity and Tumor Recurrence Rates in 137 Patients. <i>Neurosurgery</i> , 2005, 56, 546-559.	0.6	232
29	Phase II Trial of Murine ¹³¹ I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas. <i>Journal of Clinical Oncology</i> , 2002, 20, 1389-1397.	0.8	227
30	Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. <i>Journal of Neuro-Oncology</i> , 2003, 65, 27-35.	1.4	222
31	Phase I Trial of Temozolomide Plus O ⁶ -Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2005, 23, 7178-7187.	0.8	220
32	Poor drug distribution as a possible explanation for the results of the PRECISE trial. <i>Journal of Neurosurgery</i> , 2010, 113, 301-309.	0.9	219
33	Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. <i>Clinical Cancer Research</i> , 2017, 23, 1898-1909.	3.2	215
34	Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. <i>Cancer Research</i> , 2002, 62, 3335-9.	0.4	210
35	Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2010, 96, 219-230.	1.4	208
36	Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 4202-4210.	3.2	207

#	ARTICLE	IF	CITATIONS
37	Convection-enhanced delivery of therapeutics for brain disease, and its optimization. <i>Neurosurgical Focus</i> , 2006, 20, E12.	1.0	204
38	Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas. <i>Neurosurgery</i> , 2012, 70, 234-244.	0.6	204
39	Preoperative Functional MR Imaging Localization of Language and Motor Areas: Effect on Therapeutic Decision Making in Patients with Potentially Resectable Brain Tumors. <i>Radiology</i> , 2006, 240, 793-802.	3.6	193
40	Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma. <i>Clinical Cancer Research</i> , 2006, 12, 860-868.	3.2	187
41	Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. <i>Neuro-Oncology</i> , 2008, 10, 320-329.	0.6	179
42	Phase II Trial of Carmustine Plus O6-Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2277-2283.	0.8	178
43	Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 7503-7508.	3.3	177
44	Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. <i>Clinical Cancer Research</i> , 2003, 9, 4247-54.	3.2	175
45	Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas. <i>Clinical Cancer Research</i> , 2008, 14, 7068-7073.	3.2	166
46	Immunotherapy advances for glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 1441-1458.	0.6	164
47	Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. <i>Seminars in Immunology</i> , 2008, 20, 267-275.	2.7	156
48	Safety and Efficacy of Stereotactic Radiosurgery and Adjuvant Bevacizumab in Patients With Recurrent Malignant Gliomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 2018-2024.	0.4	155
49	Systemic Anti-CD25 Monoclonal Antibody Administration Safely Enhances Immunity in Murine Glioma without Eliminating Regulatory T Cells. <i>Clinical Cancer Research</i> , 2006, 12, 4294-4305.	3.2	152
50	Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 419-427.	2.0	152
51	Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme. <i>Clinical Cancer Research</i> , 2004, 10, 3216-3224.	3.2	151
52	Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). <i>Clinical Cancer Research</i> , 2002, 8, 3496-502.	3.2	138
53	Defining the Optimal Planning Target Volume in Image-Guided Stereotactic Radiosurgery of Brain Metastases: Results of a Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 100-108.	0.4	135
54	The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2011, 17, 4119-4124.	3.2	133

#	ARTICLE	IF	CITATIONS
55	Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. <i>Journal of Neuroimmunology</i> , 2000, 103, 16-25.	1.1	128
56	CONVECTION-ENHANCED DELIVERY OF CINTREDEKIN BESUDOTOX (INTERLEUKIN-13-PE38QQR) FOLLOWED BY RADIATION THERAPY WITH AND WITHOUT TEMOZOLOMIDE IN NEWLY DIAGNOSED MALIGNANT GLIOMAS. <i>Neurosurgery</i> , 2007, 61, 1031-1038.	0.6	126
57	Phase I Trial of Carmustine Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2000, 18, 3522-3528.	0.8	125
58	Vaccine-based immunotherapeutic approaches to gliomas and beyond. <i>Nature Reviews Neurology</i> , 2017, 13, 363-374.	4.9	125
59	Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2012, 107, 155-164.	1.4	123
60	Microvascular Decompression for Glossopharyngeal Neuralgia: Long-term Effectiveness and Complication Avoidance. <i>Neurosurgery</i> , 2004, 54, 884-890.	0.6	122
61	Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 270-275.	3.3	120
62	EGFRvIII-Targeted Vaccination Therapy of Malignant Glioma. <i>Brain Pathology</i> , 2009, 19, 713-723.	2.1	118
63	Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2011, 101, 57-66.	1.4	118
64	Poliovirus receptor CD155-targeted oncolysis of glioma. <i>Neuro-Oncology</i> , 2004, 6, 208-217.	0.6	116
65	A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 414-427.	2.3	113
66	Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. <i>Neuro-Oncology</i> , 2007, 9, 343-353.	0.6	112
67	Stereotactic Body Radiotherapy for Lesions of the Spine and Paraspinal Regions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1369-1375.	0.4	112
68	Immunotherapy for Brain Tumors. <i>Journal of Clinical Oncology</i> , 2017, 35, 2450-2456.	0.8	112
69	A Novel Inhibitor of Signal Transducers And Activators Of Transcription 3 Activation Is Efficacious Against Established Central Nervous System Melanoma and Inhibits Regulatory T Cells. <i>Clinical Cancer Research</i> , 2008, 14, 5759-5768.	3.2	111
70	Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study. <i>Neuro-Oncology</i> , 2008, 10, 98-103.	0.6	109
71	Clinical trial end points for high-grade glioma: the evolving landscape. <i>Neuro-Oncology</i> , 2011, 13, 353-361.	0.6	105
72	Monoclonal antibody blockade of IL-2 receptor β during lymphopenia selectively depletes regulatory T cells in mice and humans. <i>Blood</i> , 2011, 118, 3003-3012.	0.6	104

#	ARTICLE	IF	CITATIONS
73	Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 1586-1594.	3.2	103
74	Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression. <i>Journal of Clinical Investigation</i> , 2014, 124, 5352-5367.	3.9	102
75	EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma. <i>PLoS ONE</i> , 2014, 9, e94281.	1.1	99
76	A Pilot Study of IL-2R β Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma. <i>PLoS ONE</i> , 2012, 7, e31046.	1.1	98
77	Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma?. <i>Neuro-Oncology</i> , 2011, 13, 3-13.	0.6	97
78	Intracerebral Infusate Distribution by Convection-enhanced Delivery in Humans with Malignant Gliomas: Descriptive Effects of Target Anatomy and Catheter Positioning. <i>Operative Neurosurgery</i> , 2007, 60, ONS-89-ONS-99.	0.4	95
79	Thickness of Subcutaneous Fat as a Risk Factor for Infection in Cervical Spine Fusion Surgery. <i>Journal of Bone and Joint Surgery - Series A</i> , 2013, 95, 323-328.	1.4	95
80	Concurrent Stereotactic Radiosurgery and Bevacizumab in Recurrent Malignant Gliomas: A Prospective Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 873-879.	0.4	94
81	Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 189-190.	0.8	94
82	Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2007, 83, 53-60.	1.4	92
83	Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. <i>Journal of Neurosurgery</i> , 2008, 109, 874-880.	0.9	91
84	Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege. <i>Clinical Cancer Research</i> , 2014, 20, 5620-5629.	3.2	91
85	Characterization of a Spontaneous Murine Astrocytoma and Abrogation of Its Tumorigenicity by Cytokine Secretion. <i>Neurosurgery</i> , 1997, 41, 1365-1372.	0.6	88
86	Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme. <i>Immunotherapy</i> , 2014, 6, 679-690.	1.0	88
87	Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma. <i>Clinical Cancer Research</i> , 2016, 22, 582-595.	3.2	88
88	PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?. <i>Clinical Cancer Research</i> , 2020, 26, 5287-5296.	3.2	88
89	Immunotherapy of malignant brain tumors. <i>Immunological Reviews</i> , 2008, 222, 70-100.	2.8	87
90	A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. <i>Journal of Neurochemistry</i> , 2009, 109, 1079-1086.	2.1	85

#	ARTICLE	IF	CITATIONS
91	Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1049-1060.	1.3	84
92	Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. <i>Journal of Neuro-Oncology</i> , 2011, 103, 371-379.	1.4	83
93	The Evolving Modern Management of Brain Metastasis. <i>Clinical Cancer Research</i> , 2019, 25, 6570-6580.	3.2	83
94	Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. <i>Cancer Research</i> , 2018, 78, 256-264.	0.4	82
95	Dendritic Cells Pulsed with a Tumor-specific Peptide Induce Long-lasting Immunity and Are Effective against Murine Intracerebral Melanoma. <i>Neurosurgery</i> , 2002, 50, 158-166.	0.6	81
96	Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. <i>Cancer</i> , 2011, 117, 5351-5358.	2.0	80
97	The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 1087-1098.	1.4	79
98	A comprehensive outlook on intracerebral therapy of malignant gliomas. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 54-68.	2.0	79
99	The current state of immunotherapy for gliomas: an eye toward the future. <i>Journal of Neurosurgery</i> , 2019, 131, 657-666.	0.9	79
100	Bispecific antibodies engage T cells for antitumor immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 843-853.	1.4	78
101	Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. <i>Journal of Neuro-Oncology</i> , 2012, 106, 409-415.	1.4	78
102	Recurrence of a cerebral arteriovenous malformation after surgical excision. <i>Journal of Neurosurgery</i> , 1996, 84, 879-882.	0.9	77
103	Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. <i>Clinical Cancer Research</i> , 2019, 25, 2042-2048.	3.2	77
104	Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. <i>Nature Communications</i> , 2021, 12, 352.	5.8	77
105	Addition of Bevacizumab to Standard Radiation Therapy and Daily Temozolomide Is Associated With Minimal Toxicity in Newly Diagnosed Glioblastoma Multiforme. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 58-66.	0.4	74
106	Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells. <i>Clinical Cancer Research</i> , 2014, 20, 2684-2694.	3.2	74
107	A Supramolecular Vaccine Platform Based on α -Helical Peptide Nanofibers. <i>ACS Biomaterials Science and Engineering</i> , 2017, 3, 3128-3132.	2.6	74
108	IgE, allergy, and risk of glioma: Update from the San Francisco Bay Area Adult Glioma Study in the Temozolomide era. <i>International Journal of Cancer</i> , 2009, 125, 680-687.	2.3	73

#	ARTICLE	IF	CITATIONS
109	Therapeutic approaches for HER2-positive brain metastases: Circumventing the blood-brain barrier. <i>Cancer Treatment Reviews</i> , 2013, 39, 261-269.	3.4	73
110	Current multidisciplinary management of brain metastases. <i>Cancer</i> , 2020, 126, 1390-1406.	2.0	70
111	Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. <i>OncImmunity</i> , 2018, 7, e1434464.	2.1	69
112	Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. <i>Neurosurgical Focus</i> , 2006, 20, E15.	1.0	68
113	Induction of Hyperintense Signal on T2-Weighted MR Images Correlates with Infusion Distribution from Intracerebral Convection-Enhanced Delivery of a Tumor-Targeted Cytotoxin. <i>American Journal of Roentgenology</i> , 2007, 188, 703-709.	1.0	67
114	The Role of Tregs in Glioma-Mediated Immunosuppression: Potential Target for Intervention. <i>Neurosurgery Clinics of North America</i> , 2010, 21, 125-137.	0.8	67
115	Colocalization of Gadolinium-Diethylene Triamine Pentaacetic Acid With High-Molecular-Weight Molecules After Intracerebral Convection-Enhanced Delivery in Humans. <i>Neurosurgery</i> , 2011, 69, 668-676.	0.6	67
116	Oncolytic polio virotherapy of cancer. <i>Cancer</i> , 2014, 120, 3277-3286.	2.0	67
117	Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 5297-5303.	3.2	67
118	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602.	3.2	67
119	Dendritic Cells Pulsed with a Tumor-specific Peptide Induce Long-lasting Immunity and Are Effective against Murine Intracerebral Melanoma. <i>Neurosurgery</i> , 2002, 50, 158-166.	0.6	66
120	Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T Cells in Patients with Malignant Glioma Reveals Differential Expression of the Immunologic Transcriptome Compared with T Cells from Healthy Volunteers. <i>Clinical Cancer Research</i> , 2006, 12, 7306-7315.	3.2	65
121	Combating immunosuppression in glioma. <i>Future Oncology</i> , 2008, 4, 433-442.	1.1	65
122	Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. <i>Journal of Neuro-Oncology</i> , 2011, 101, 267-277.	1.4	64
123	Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. <i>Clinical Cancer Research</i> , 2003, 9, 5514-20.	3.2	63
124	Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody. <i>Cancer Immunology Research</i> , 2013, 1, 163-167.	1.6	61
125	Oncolytic virus-derived type I interferon restricts CAR T cell therapy. <i>Nature Communications</i> , 2020, 11, 3187.	5.8	61
126	An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. <i>Expert Review of Vaccines</i> , 2013, 12, 597-615.	2.0	60

#	ARTICLE	IF	CITATIONS
127	Phase II Trial of Gliadel plus <i>l</i> -6-Benzylguanine in Adults with Recurrent Glioblastoma Multiforme. <i>Clinical Cancer Research</i> , 2009, 15, 1064-1068.	3.2	59
128	Are BiTEs the "missing link" in cancer therapy?. <i>Oncolmmunology</i> , 2015, 4, e1008339.	2.1	59
129	Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles. <i>Oncolmmunology</i> , 2017, 6, e1256527.	2.1	59
130	Paraganglioma of the Head and Neck. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 304-307.	0.6	57
131	Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice. <i>PLoS ONE</i> , 2013, 8, e59082.	1.1	56
132	ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2009-2009.	0.8	56
133	Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus.. <i>Clinical Cancer Research</i> , 2006, 12, 1349-1354.	3.2	55
134	Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. <i>Journal of Clinical Investigation</i> , 2013, 123, 3135-3145.	3.9	55
135	Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: Case study. <i>Neuro-Oncology</i> , 2005, 7, 90-96.	0.6	54
136	Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. <i>Neurosurgical Focus</i> , 2006, 20, E14.	1.0	54
137	Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. <i>Journal of Neuro-Oncology</i> , 2009, 95, 393-400.	1.4	53
138	Worse outcomes for patients undergoing brain tumor and cerebrovascular procedures following the ACGME resident duty-hour restrictions. <i>Journal of Neurosurgery</i> , 2014, 121, 262-276.	0.9	52
139	Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3010-3010.	0.8	52
140	Monoclonal antibody therapy of human gliomas: current status and future approaches. <i>Cancer and Metastasis Reviews</i> , 1999, 18, 451-464.	2.7	51
141	Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts. <i>Clinical Cancer Research</i> , 2019, 25, 358-368.	3.2	51
142	Treatment of Intracerebral Neoplasia and Neoplastic Meningitis with Regional Delivery of Oncolytic Recombinant Poliovirus. <i>Clinical Cancer Research</i> , 2004, 10, 4831-4838.	3.2	49
143	Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. <i>Journal of Immunological Methods</i> , 2008, 339, 74-81.	0.6	48
144	A Novel Method for Volumetric MRI Response Assessment of Enhancing Brain Tumors. <i>PLoS ONE</i> , 2011, 6, e16031.	1.1	48

#	ARTICLE	IF	CITATIONS
145	Phase I study of Gliadel [®] wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. <i>Neuro-Oncology</i> , 2001, 3, 246-250.	0.6	47
146	Contemporary Surgical Management of Vestibular Schwannomas. <i>Operative Neurosurgery</i> , 2013, 72, ons103-ons115.	0.4	47
147	Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses. <i>Journal of Clinical Investigation</i> , 2020, 130, 774-788.	3.9	47
148	Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. <i>Journal of Neuro-Oncology</i> , 2010, 98, 1-7.	1.4	46
149	Dorsal root entry zone lesions for intractable pain after trauma to the conus medullaris and cauda equina. <i>Journal of Neurosurgery</i> , 1995, 82, 28-34.	0.9	44
150	Single fraction stereotactic radiosurgery for multiple brain metastases. <i>Advances in Radiation Oncology</i> , 2017, 2, 555-563.	0.6	44
151	Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of β -particle-emitting ²¹¹ At-labeled trastuzumab. <i>Nuclear Medicine and Biology</i> , 2009, 36, 659-669.	0.3	43
152	ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2016, 18, vi17-vi18.	0.6	43
153	Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. <i>Neuro-Oncology</i> , 2004, 6, 134-144.	0.6	42
154	Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor. <i>Journal of Neuro-Oncology</i> , 2021, 151, 55-62.	1.4	42
155	Immunotherapy Approaches for Malignant Glioma From 2007 to 2009. <i>Current Neurology and Neuroscience Reports</i> , 2010, 10, 259-266.	2.0	41
156	Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2012, 108, 499-506.	1.4	41
157	Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas. <i>Oncolimmunology</i> , 2015, 4, e994374.	2.1	41
158	Peptide vaccines for the treatment of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2015, 123, 433-440.	1.4	41
159	A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2079-TPS2079.	0.8	41
160	Recurrent Malignant Gliomas. <i>Seminars in Radiation Oncology</i> , 2014, 24, 289-298.	1.0	40
161	Prospect of rindopepimut in the treatment of glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 507-513.	1.4	40
162	Metastatic Melanoma to the Spine Demographics, Risk Factors, and Prognosis in 114 Patients. <i>Spine</i> , 1995, 20, 2141-2146.	1.0	39

#	ARTICLE	IF	CITATIONS
163	Molecular strategies for the treatment of malignant glioma—genes, viruses, and vaccines. <i>Neurosurgical Review</i> , 2008, 31, 141-155.	1.2	39
164	Selective Modification of Antigen-Specific T Cells by RNA Electroporation. <i>Human Gene Therapy</i> , 2008, 19, 511-521.	1.4	39
165	Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2009, 11, 556-561.	0.6	39
166	A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. <i>Clinical Cancer Research</i> , 2018, 24, 3611-3631.	3.2	39
167	Toward Effective Immunotherapy for the Treatment of Malignant Brain Tumors. <i>Neurotherapeutics</i> , 2009, 6, 527-538.	2.1	37
168	CAR T cells and checkpoint inhibition for the treatment of glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 579-591.	1.4	37
169	EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 115-121.	2.0	36
170	Immunotherapy for malignant glioma. , 2015, 6, 68.		36
171	Comparative study of α -helical and β -sheet self-assembled peptide nanofiber vaccine platforms: influence of integrated T-cell epitopes. <i>Biomaterials Science</i> , 2020, 8, 3522-3535.	2.6	35
172	A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo. <i>Journal of Neuroimmunology</i> , 1997, 78, 34-46.	1.1	34
173	Emerging immunotherapies for glioblastoma. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 133-145.	1.0	34
174	The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. <i>Journal of Neuro-Oncology</i> , 2003, 64, 161-176.	1.4	33
175	Advances and challenges: dendritic cell vaccination strategies for glioblastoma. <i>Expert Review of Vaccines</i> , 2017, 16, 27-36.	2.0	33
176	Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with ¹³¹ I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. <i>Journal of Nuclear Medicine</i> , 2006, 47, 912-8.	2.8	32
177	Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells. <i>Journal of Clinical Neuroscience</i> , 2018, 56, 163-168.	0.8	31
178	Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody. <i>Oncolmmunology</i> , 2013, 2, e26757.	2.1	30
179	MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation. <i>Cancer Research</i> , 2019, 79, 3383-3394.	0.4	30
180	Impact of PhD training on scholarship in a neurosurgical career. <i>Journal of Neurosurgery</i> , 2014, 120, 730-735.	0.9	29

#	ARTICLE	IF	CITATIONS
181	Epidermal growth factor receptor and variant III targeted immunotherapy. <i>Neuro-Oncology</i> , 2014, 16, viii20-viii25.	0.6	29
182	Convection Enhanced Delivery of Macromolecules for Brain Tumors. <i>Current Drug Discovery Technologies</i> , 2012, 9, 305-310.	0.6	29
183	Local production of TGF β 1 inhibits cerebral edema, enhances TNF- α induced apoptosis and improves survival in a murine glioma model. <i>Journal of Neuroimmunology</i> , 1998, 86, 46-52.	1.1	28
184	Phase 1 trial of temozolomide plus irinotecan plus O ⁶ -methylguanine in adults with recurrent malignant glioma. <i>Cancer</i> , 2009, 115, 2964-2970.	2.0	28
185	A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma. <i>Journal of Neurosurgery</i> , 2014, 121, 536-542.	0.9	28
186	Rapid Reprogramming of Primary Human Astrocytes into Potent Tumor-Initiating Cells with Defined Genetic Factors. <i>Cancer Research</i> , 2016, 76, 5143-5150.	0.4	28
187	Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis. <i>Neuro-Oncology</i> , 2017, 19, 1391-1397.	0.6	28
188	Is Cytomegalovirus a Therapeutic Target in Glioblastoma?. <i>Clinical Cancer Research</i> , 2011, 17, 4619-4621.	3.2	27
189	Bevacizumab-Induced Reversible Posterior Leukoencephalopathy Syndrome and Successful Retreatment in a Patient With Glioblastoma. <i>Journal of Clinical Oncology</i> , 2011, 29, e739-e742.	0.8	26
190	Cryptococcal meningitis in patients with glioma: a report of two cases. <i>Journal of Neuro-Oncology</i> , 2008, 89, 51-53.	1.4	25
191	Monitoring Radiographic Brain Tumor Progression. <i>Toxins</i> , 2011, 3, 191-200.	1.5	25
192	Vaccination strategies for neuro-oncology: Table 1.. <i>Neuro-Oncology</i> , 2015, 17, vii15-vii25.	0.6	25
193	Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. <i>Neuro-Oncology</i> , 2004, 6, 145-153.	0.6	24
194	Toxin-Based Targeted Therapy for Malignant Brain Tumors. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-15.	3.3	24
195	Stereotactic Radiosurgery and Bevacizumab for Recurrent Glioblastoma Multiforme. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 695-699.	2.3	24
196	Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma: Table 1.. <i>Neuro-Oncology</i> , 2015, 17, 1043-1045.	0.6	24
197	Delivering therapy to target: improving the odds for successful drug development. <i>Therapeutic Delivery</i> , 2016, 7, 457-481.	1.2	24
198	Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 3916-3925.	3.2	24

#	ARTICLE	IF	CITATIONS
199	Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143.. Journal of Clinical Oncology, 2016, 34, 2014-2014.	0.8	24
200	Immunological targeting of cytomegalovirus for glioblastoma therapy. OncoImmunology, 2014, 3, e29289.	2.1	23
201	Enzyme redesign guided by cancer-derived IDH1 mutations. Nature Chemical Biology, 2012, 8, 887-889.	3.9	22
202	Clinicopathological characteristics and treatment of rhabdoid glioblastoma. Journal of Neurosurgery, 2013, 119, 412-419.	0.9	22
203	Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma. Journal of Neuro-Oncology, 2015, 125, 65-74.	1.4	22
204	Adoptive Immunotherapy for Malignant Glioma. Cancer Journal (Sudbury, Mass), 2003, 9, 157-166.	1.0	21
205	Clinical Applications of a Peptide-Based Vaccine for Glioblastoma. Neurosurgery Clinics of North America, 2010, 21, 95-109.	0.8	21
206	Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncology, 2013, 9, 977-990.	1.1	21
207	Alternating Electric Fields for the Treatment of Glioblastoma. JAMA - Journal of the American Medical Association, 2015, 314, 2511.	3.8	21
208	Immunomodulation for glioblastoma. Current Opinion in Neurology, 2017, 30, 361-369.	1.8	21
209	First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach. , 2020, 8, e000213.		21
210	Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. Cancer Immunology, Immunotherapy, 2002, 50, 639-652.	2.0	20
211	Imaging of Convection Enhanced Delivery of Toxins in Humans. Toxins, 2011, 3, 201-206.	1.5	20
212	An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. Expert Review of Clinical Pharmacology, 2013, 6, 375-386.	1.3	20
213	Isocitrate dehydrogenase 1: what it means to the neurosurgeon. Journal of Neurosurgery, 2013, 118, 1176-1180.	0.9	20
214	IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v109.1-v109.	0.6	20
215	Severe Adverse Immunologic Reaction in a Patient with Glioblastoma Receiving Autologous Dendritic Cell Vaccines Combined with GM-CSF and Dose-Intensified Temozolomide. Cancer Immunology Research, 2015, 3, 320-325.	1.6	20
216	Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma. Expert Opinion on Biological Therapy, 2015, 15, 79-94.	1.4	20

#	ARTICLE	IF	CITATIONS
217	Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy. <i>Oncolimmunology</i> , 2014, 3, e944054.	2.1	19
218	Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2047-2061.	0.9	19
219	The Safety of available immunotherapy for the treatment of glioblastoma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 277-287.	1.0	19
220	Targeting Immunometabolism in Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 696402.	1.3	19
221	Rindopepimut. <i>Drugs of the Future</i> , 2013, 38, 147.	0.0	19
222	Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. <i>Journal of Neuro-Oncology</i> , 1999, 44, 233-241.	1.4	18
223	Editorial: Methodology and reporting of meta-analyses in the neurosurgical literature. <i>Journal of Neurosurgery</i> , 2014, 120, 791-795.	0.9	18
224	A Review of Anesthesia Simulation in Low-Income Countries. <i>Current Anesthesiology Reports</i> , 2019, 9, 1-9.	0.9	18
225	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 585-593.	3.2	18
226	Solitary Eosinophilic Granuloma Invading the Clivus of an Adult. <i>Neurosurgery</i> , 1992, 31, 755-757.	0.6	18
227	Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac025.	0.4	18
228	Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care. <i>Journal of Visualized Experiments</i> , 2015, , .	0.2	17
229	Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2061-2061.	0.8	17
230	Facial pain due to vascular lesions of the brain stem relieved by dorsal root entry zone lesions in the nucleus caudalis. <i>Journal of Neurosurgery</i> , 1992, 77, 473-475.	0.9	16
231	A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system. <i>Oncolimmunology</i> , 2013, 2, e23639.	2.1	16
232	107 ReACT. <i>Neurosurgery</i> , 2015, 62, 198-199.	0.6	16
233	How does the immune system attack cancer?. <i>Current Problems in Surgery</i> , 2004, 41, 15-132.	0.6	14
234	Editorial: SEER insights. <i>Journal of Neurosurgery</i> , 2014, 120, 297-299.	0.9	14

#	ARTICLE	IF	CITATIONS
235	Pharmacokinetic Analysis of a Novel Human EGFRvIII:CD3 Bispecific Antibody in Plasma and Whole Blood Using a High-Resolution Targeted Mass Spectrometry Approach. <i>Journal of Proteome Research</i> , 2019, 18, 3032-3041.	1.8	14
236	Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 717-732.	1.1	13
237	BlyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 983-987.	2.0	13
238	Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity. <i>Clinical Cancer Research</i> , 2016, 22, 5164-5166.	3.2	13
239	Institutional Review of Mortality in 5434 Consecutive Neurosurgery Patients: Are We Improving?. <i>Neurosurgery</i> , 2018, 83, 1269-1276.	0.6	13
240	Processing of natural resourced hydroxyapatite ceramics from fish scale. <i>Advances in Applied Ceramics</i> , 2010, 109, 234-239.	0.6	12
241	Solitary Eosinophilic Granuloma Invading the Clivus of an Adult. <i>Neurosurgery</i> , 1992, 31, 755-757.	0.6	11
242	Clinical immunotherapy for brain tumors. <i>Neuroimaging Clinics of North America</i> , 2002, 12, 641-664.	0.5	11
243	Viruses in the treatment of brain tumors. <i>Neuroimaging Clinics of North America</i> , 2002, 12, 553-570.	0.5	11
244	Editorial. <i>Journal of Neurosurgery</i> , 2011, 115, 463-466.	0.9	11
245	Regulatory T Cells Move in When Gliomas Say "No". <i>Clinical Cancer Research</i> , 2012, 18, 6086-6088.	3.2	11
246	Antibody-Based Immunotherapy for Malignant Glioma. <i>Seminars in Oncology</i> , 2014, 41, 496-510.	0.8	11
247	Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development. <i>Journal of Neurochemistry</i> , 2015, 133, 730-738.	2.1	11
248	miR-23a blockade enhances adoptive T cell transfer therapy by preserving immune-competence in the tumor microenvironment. <i>OncImmunology</i> , 2015, 4, e990803.	2.1	11
249	CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response. <i>OncImmunology</i> , 2018, 7, e1502904.	2.1	11
250	Effective effectors: How T cells access and infiltrate the central nervous system. , 2019, 197, 52-60.		11
251	Outcomes in Patients With 4 to 10 Brain Metastases Treated With Dose-Adapted Single-Isocenter Multitarget Stereotactic Radiosurgery: A Prospective Study. <i>Advances in Radiation Oncology</i> , 2021, 6, 100760.	0.6	11
252	For whom the T cells troll? Bispecific T-cell engagers in glioblastoma. , 2021, 9, e003679.		11

#	ARTICLE	IF	CITATIONS
253	Viruses in the treatment of malignant glioma. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 321-324.	1.4	10
254	Radiotherapy and Radiosurgery for Tumors of the Central Nervous System. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 445-461.	0.6	10
255	Determinants of Intraparenchymal Infusion Distributions: Modeling and Analyses of Human Glioblastoma Trials. <i>Pharmaceutics</i> , 2020, 12, 895.	2.0	10
256	Enhancing T Cell Chemotaxis and Infiltration in Glioblastoma. <i>Cancers</i> , 2021, 13, 5367.	1.7	10
257	Reply to M.S. Lesniak. <i>Journal of Clinical Oncology</i> , 2011, 29, 3105-3106.	0.8	9
258	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2068-2068.	0.8	9
259	The Use of Motor Mapping to Aid Resection of Eloquent Gliomas. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 215-225.	0.8	8
260	Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence. <i>Oncolmmunology</i> , 2014, 3, e944059.	2.1	8
261	Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1147-1158.	1.3	8
262	A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neopeptide. <i>Npj Vaccines</i> , 2021, 6, 12.	2.9	8
263	Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13526-e13526.	0.8	8
264	Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity. <i>Journal of Neuroimmunology</i> , 2007, 182, 63-72.	1.1	7
265	Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration. <i>Journal of Neuro-Oncology</i> , 2010, 98, 427-430.	1.4	7
266	Stereotactic Radiosurgery in the Treatment of a Dural Carotid-Cavernous Fistula. <i>Journal of Neuro-Ophthalmology</i> , 2010, 30, 138-144.	0.4	7
267	A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1649-1662.	2.0	7
268	MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2513-2513.	0.8	7
269	Title is missing!. <i>Journal of Neuro-Oncology</i> , 2003, 64, 161-176.	1.4	6
270	Treatment of Neoplastic Meningitis With Intrathecal 9-Nitro-camptothecin. <i>Neurologia Medico-Chirurgica</i> , 2006, 46, 485-490.	1.0	6

#	ARTICLE	IF	CITATIONS
271	Cholesterol granuloma of the lateral ventricle. <i>Journal of Neurosurgery</i> , 2008, 108, 357-360.	0.9	6
272	IMCT-03SAFETY AND ACTIVITY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA: UPDATED RESULTS FROM CHECKMATE-143. <i>Neuro-Oncology</i> , 2015, 17, v107.3-v107.	0.6	6
273	ATIM-16. NIVOLUMAB COMBINED WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM PHASE 1 SAFETY COHORTS IN CHECKMATE 143. <i>Neuro-Oncology</i> , 2016, 18, vi21-vi21.	0.6	6
274	Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 205-211.	2.0	6
275	Phase I trial of combination of antitumor immunotherapy targeted against <i>cytomegalovirus</i> plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).. <i>Journal of Clinical Oncology</i> , 2016, 34, e13518-e13518.	0.8	6
276	EGFRvIII: an oncogene deletion mutant cell surface receptor target expressed by multiple tumour types. <i>Expert Opinion on Therapeutic Targets</i> , 2000, 4, 497-514.	1.0	5
277	Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis. <i>Journal of Immunological Methods</i> , 2013, 395, 14-20.	0.6	5
278	Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy. <i>Methods in Molecular Biology</i> , 2016, 1403, 819-838.	0.4	5
279	Accuracy of Novel Computed Tomography-Guided Frameless Stereotactic Drilling and Catheter System in Human Cadavers. <i>World Neurosurgery</i> , 2017, 106, 757-763.	0.7	5
280	Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply. <i>Lancet Oncology</i> , 2017, 18, e709-e710.	5.1	5
281	ATIM-27. TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES. <i>Neuro-Oncology</i> , 2019, 21, vi7-vi7.	0.6	5
282	A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2022, 40, e14015-e14015.	0.8	5
283	Reproducibility of outcomes in sequential trials using CMV-targeted dendritic cell vaccination for glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2005-2005.	0.8	5
284	Editorial. <i>Journal of Neurosurgery</i> , 2011, 115, 245-247.	0.9	4
285	Editorial: Subarachnoid hemorrhage trials. <i>Journal of Neurosurgery</i> , 2013, 118, 1-2.	0.9	4
286	Editorial: Turning fluorescence into black and white. <i>Journal of Neurosurgery</i> , 2015, 122, 1356-1359.	0.9	4
287	A simple and enzyme-free method for processing infiltrating lymphocytes from small mouse tumors for ELISpot analysis. <i>Journal of Immunological Methods</i> , 2018, 459, 90-93.	0.6	4
288	GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody. <i>PLoS ONE</i> , 2020, 15, e0236374.	1.1	4

#	ARTICLE	IF	CITATIONS
289	MDNA55: A locally administered IL4 guided toxin as a targeted treatment for recurrent glioblastoma.. Journal of Clinical Oncology, 2019, 37, 2039-2039.	0.8	4
290	Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas. Current Drug Discovery Technologies, 2012, 9, 237-255.	0.6	4
291	Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).. Journal of Clinical Oncology, 2020, 38, 2566-2566.	0.8	4
292	Editorial: Not everything that matters can be measured and not everything that can be measured matters. Journal of Neurosurgery, 2015, 123, 543-546.	0.9	3
293	ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE. Neuro-Oncology, 2019, 21, vi12-vi12.	0.6	3
294	Convection-Enhanced Drug Delivery to the Brain. Neuromethods, 2010, , 291-318.	0.2	3
295	Low-dose whole brain radiotherapy combined with radiosurgery for primary CNS lymphoma achieving partial response to induction methotrexate-based chemotherapy. Journal of Radiosurgery and SBRT, 2014, 3, 37-42.	0.2	3
296	Editorial: Low-grade glioma. Journal of Neurosurgery, 2011, 114, 563-565.	0.9	2
297	Editorial: Resection of vestibular schwannomas. Journal of Neurosurgery, 2011, 114, 1216-1217.	0.9	2
298	The limitations of imaging response criteria. Lancet Oncology, The, 2012, 13, 1064-1065.	5.1	2
299	Editorial on "Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccination for Recurrent Glioblastoma: A Phase II, Single Arm Trial". Neuro-Oncology, 2014, 16, 169-170.	0.6	2
300	Editorial: Patient validation of retrospective data. Journal of Neurosurgery, 2015, 123, 969-971.	0.9	2
301	ATIM-36. DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). Neuro-Oncology, 2018, 20, vi9-vi9.	0.6	2
302	HGG-22. PHASE 1b STUDY POLIO VACCINE SABIN-RHINOVIRUS POLIOVIRUS (PVSRIPO) FOR RECURRENT MALIGNANT GLIOMA IN CHILDREN. Neuro-Oncology, 2018, 20, i93-i93.	0.6	2
303	Brain Metastases from Malignant Melanoma. , 2005, , 430-438.		2
304	Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma.. Journal of Clinical Oncology, 2017, 35, e13532-e13532.	0.8	2
305	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.. Journal of Clinical Oncology, 2019, 37, 2060-2060.	0.8	2
306	Generation of Tumor Targeted Dendritic Cell Vaccines with Improved Immunogenic and Migratory Phenotype. Methods in Molecular Biology, 2022, 2410, 609-626.	0.4	2

#	ARTICLE	IF	CITATIONS
307	The gravitational shunt: An alternative approach to cerebrospinal fluid shunting. <i>World Neurosurgery</i> , 1993, 40, 112-118.	1.3	1
308	Editorial: Epidemiology. <i>Journal of Neurosurgery</i> , 2011, 115, 256-258.	0.9	1
309	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2011, 29, e519-e520.	0.8	1
310	A promising cancer vaccine. <i>Future Oncology</i> , 2011, 7, 331-334.	1.1	1
311	Editorial. <i>Journal of Neurosurgery</i> , 2012, 116, 336-340.	0.9	1
312	Editorial. <i>Journal of Neurosurgery</i> , 2012, 116, 346-348.	0.9	1
313	Editorial: Convection-enhanced delivery. <i>Journal of Neurosurgery</i> , 2012, 117, 1126-1127.	0.9	1
314	Editorial. <i>Journal of Neurosurgery</i> , 2012, 116, 280-282.	0.9	1
315	Complete response to steroids in dural inflammatory pseudotumor associated with Still's disease. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 1445-1448.	0.8	1
316	Genetics of glioma. , 0, , 1-23.		1
317	Advances in Immunotherapy. <i>Neurosurgery</i> , 2016, 63, 85-87.	0.6	1
318	The clinical and financial impact of a pediatric surgical neuro-oncology clinical trial. <i>Journal of Neuro-Oncology</i> , 2017, 132, 83-87.	1.4	1
319	Obituary. Robert H. Wilkins, MD, 1934–2017. <i>Journal of Neurosurgery</i> , 2017, 127, 1457-1458.	0.9	1
320	ATIM-05. INTRATUMORAL DELIVERY OF MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, BY MRI-GUIDED CONVECTIVE DELIVERY FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi1-vi2.	0.6	1
321	ATIM-30. COMBATING RECURRENT GLIOBLASTOMA WITH MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, THROUGH MRI-GUIDED CONVECTIVE DELIVERY. <i>Neuro-Oncology</i> , 2019, 21, vi8-vi8.	0.6	1
322	ATIM-24. DOSE FINDING AND DOSE EXPANSION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). <i>Neuro-Oncology</i> , 2019, 21, vi6-vi6.	0.6	1
323	CLRM-09. INCORPORATING EXTERNAL CONTROL ARM IN MDNA55 RECURRENT GLIOBLASTOMA REGISTRATION TRIAL. <i>Neuro-Oncology Advances</i> , 2021, 3, iv3-iv3.	0.4	1
324	Cytokine-Based Gene Therapy for Brain Tumors. , 1998, , 231-294.		1

#	ARTICLE	IF	CITATIONS
325	The effect of adoptive transfer of ex vivo activated T cells on the efficacy and tumor penetrance of intravenously-administered CD3-engaging bispecific antibody.. Journal of Clinical Oncology, 2019, 37, 30-30.	0.8	1
326	Editorial: Resection and survival. Journal of Neurosurgery, 2012, 116, 1169-1171.	0.9	0
327	Enhanced Oncolytic Virotherapy Through Oxidative Stress Inhibition. Molecular Therapy, 2013, 21, 1981-1983.	3.7	0
328	IMCT-19COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM). Neuro-Oncology, 2015, 17, v111.4-v112.	0.6	0
329	Design and statistical analysis of clinical trials for glioma therapy. , 0, , 169-189.		0
330	Radiation therapy for gliomas. , 0, , 49-75.		0
331	Immunotherapy for gliomas. , 0, , 91-120.		0
332	Neuropathology of gliomas. , 0, , 146-168.		0
333	Health-related quality of life in glioma patients. , 0, , 190-204.		0
334	Chemotherapy for gliomas. , 0, , 76-90.		0
335	IMST-38. CAR T CELLS INDUCE COMPLETE REGRESSION OF MURINE GLIOBLASTOMA AFTER PRECONDITIONING HOSTS WITH TEMOZOLOMIDE. Neuro-Oncology, 2016, 18, vi94-vi95.	0.6	0
336	IMST-44. LYMPHOPENIA ENHANCES THE EFFICACY OF CAR T CELLS DELIVERED LOCO-REGIONALLY IN THE BRAIN FOR THE TREATMENT OF GLIOBLASTOMA. Neuro-Oncology, 2016, 18, vi96-vi96.	0.6	0
337	Glioma surgery. , 0, , 24-48.		0
338	Neuroradiology of gliomas. , 0, , 121-145.		0
339	Immunotherapy for High-Grade Gliomas. , 2017, , 177-192.		0
340	DDIS-02. NOVEL BISPECIFIC ACTIVATOR OF MACROPHAGES FOR THE TREATMENT OF GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi69-vi69.	0.6	0
341	ATIM-27. INTRATUMORAL ADMINISTRATION OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF MUTATIONAL RESPONSE CORRELATES. Neuro-Oncology, 2018, 20, vi7-vi7.	0.6	0
342	RBTT-02. ENHANCING VACCINE RESPONSES WITH DOSE-INTENSIFIED TEMOZOLOMIDE IN GLIOBLASTOMA: INITIATION OF THE I-ATTAC TRIAL. Neuro-Oncology, 2018, 20, vi234-vi234.	0.6	0

#	ARTICLE	IF	CITATIONS
343	Overview of Vaccine Strategies Against Epidermal Growth Factor Receptor in Brain Tumors. , 2018, , 693-705.		0
344	Introduction. Update on adult neuro-oncology. Neurosurgical Focus, 2018, 44, E1.	1.0	0
345	Reply to "Assembling the brain trust: the multidisciplinary imperative in neuro-oncology"™. Nature Reviews Clinical Oncology, 2019, 16, 522-523.	12.5	0
346	PDCT-10. FEASIBILITY OF LEUKAPHERESIS FOR HARVESTING MONOCYTES AND GENERATING AUTOLOGOUS DENDRITIC CELL VACCINES IN CHILDREN WITH MALIGNANT BRAIN TUMORS. Neuro-Oncology, 2019, 21, vi185-vi185.	0.6	0
347	ATIM-31. SAFETY OF TUMOR-SPECIFIC PEPTIDE VACCINE TARGETING ISOCITRATE DEHYDROGENASE 1 MUTATION IN RECURRENT RESECTABLE LOW GRADE GLIOMA PATIENTS. Neuro-Oncology, 2019, 21, vi8-vi8.	0.6	0
348	EXTH-09. FIRST-IN-HUMAN DOSING CONSIDERATIONS OF A BISPECIFIC ANTIBODY FOR TREATING GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi84-vi84.	0.6	0
349	Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy. , 2021, , 635-665.		0
350	Novel Therapeutic Approaches for High-Grade Gliomas. Frontiers in Neuroscience, 2004, , 155-180.	0.0	0
351	Malignant Glioma Immunotherapy: A Peptide Vaccine from Bench to Bedside. , 2011, , 349-356.		0
352	Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).. Journal of Clinical Oncology, 2015, 33, e13030-e13030.	0.8	0
353	Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).. Journal of Clinical Oncology, 2017, 35, e13533-e13533.	0.8	0
354	A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma.. Journal of Clinical Oncology, 2022, 40, TPS2076-TPS2076.	0.8	0